Locations

San Diego County

3020 Children's Way
MC 5114
San Diego, CA 92123

Specialty

Allergy/Immunology

Organization

Rady Children's Specialists of San Diego

Medical Group / IPA

CPMG/RCHN/RCSSD

Medical School

Washington University

Residency

Barnes Jewish Hospital

Fellowship

University of California Los Angeles

Board Certifications

Allergy/Immunology

Bio

Dr. Bob Geng is an allergist/immunologist at Rady Children's Hospital-San Diego and an assistant clinical professor at UC San Diego School of Medicine.

Dr. Geng earned his bachelors and masters degrees from Georgetown University. He then received his medical degree and residency training at Washington University School of Medicine in St. Louis before completing a fellowship in allergy and immunology at UC Los Angeles. He is board certified in internal medicine, allergy and immunology and clinical pharmacology.

Dr. Geng sees both pediatric and adult patients for allergic and immunologic conditions. He has a special interest in allergic conditions of the upper and lower airways as well as primary immunodeficiency disorders in both children and adults. In addition to general allergy clinics, he currently has a monthly immunology clinic focusing on primary immunodeficiency as well as a monthly Severe Asthma Clinic focusing on difficult-to-manage pediatric asthma patients.

Given his background in clinical pharmacology, Dr. Geng has an interest in clinical research, particularly in bringing novel and advanced therapies to children with allergic and immunologic disorders. He is currently conducting several clinical trials in moderate to severe asthma and primary immunodeficiency. Please contact him if you have any interest in having your child participate in any clinical studies.

Publications

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
Magnolo N, Cameron MC, Shahriari M, Geng B, Calimlim BM, Teixeira H, Hu X, Yang Y, Liu Y, Zhang S, Sancho Sanchez C, Altman K, Langley RG

The role of OX40L/OX40 axis signalling in atopic dermatitis.
Guttman-Yassky E, Croft M, Geng B, Rynkiewicz N, Lucchesi D, Peakman M, van Krinks C, Valdecantos W, Xing H, Weidinger S

Corrigendum: Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.
Geng B, Clark K, Evangelista M, Wolford E

Multidisciplinary atopic dermatitis program: A novel approach to managing difficult-to-control atopic dermatitis patients.
Tracy A, Loop L, Bhatti S, Anterasian C, Kellogg C, Smiley K, Wu A, Geng B, Eichenfield L

Implementation of a pediatric synchronous multidisciplinary severe asthma clinic and real-world outcomes.
Patel D, Revier MD, Tambay A, Geng B

Low rates of headache and migraine associated with intravenous immunoglobulin infusion using a 15-minute rate escalation protocol in 123 patients with primary immunodeficiency.
Geng B, Clark K, Evangelista M, Wolford E

Rapid genome sequencing identifies novel variants in complement factor I.
Rodriguez KM, Vaught J, Dilley M, Ellsworth K, Heinen A, Abud EM, Zhang Y, Smith RJH, Sheets R, Geng B, Hoffman HM, Worthen HM, Dimmock D, Coufal NG

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies.
Kobayashi RH, Gupta S, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Turpel-Kantor E, Litzman J

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
Kobayashi RH, Litzman J, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Höller S, Turpel-Kantor E, Kreuwel H, Speer JC, Gupta S

A novel case of chronic spontaneous urticaria associated chronic myelogenous leukemia with rapid resolution upon treatment with imatinib.
Tracy A, Kahn J, Geng B, Russo M, Safai B

Allergen Content and Protease Activity in Milk Feeds from Mothers of Preterm Infants.
Luskin K, Mortazavi D, Bai-Tong S, Bertrand K, Chambers C, Schulkers-Escalante K, Ahmad A, Luedtke S, O'Donoghue AJ, Ghassemian M, Geng B, Leibel SL, Leibel SA

Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients.
Geier CB, Ellison M, Cruz R, Pawar S, Leiss-Piller A, Zmajkovicova K, McNulty SM, Yilmaz M, Evans MO 2nd, Gordon S, Ujhazi B, Wiest I, Abolhassani H, Aghamohammadi A, Barmettler S, Bhar S, Bondarenko A, Bolyard AA, Buchbinder D, Cada M, Cavieres M, Connelly JA, Dale DC, Deordieva E, Dorsey MJ, Drysdale SB, Ehl S, Elfeky R, Fioredda F, Firkin F, Förster-Waldl E, Geng B, Goda V, Gonzalez-Granado L, Grunebaum E, Grzesk E, Henrickson SE, Hilfanova A, Hiwatari M, Imai C, Ip W, Jyonouchi S, Kanegane H, Kawahara Y, Khojah AM, Kim VH, Kojić M, Kołtan S, Krivan G, Langguth D, Lau YL, Leung D, Miano M, Mersyanova I, Mousallem T, Muskat M, Naoum FA, Noronha SA, Ouederni M, Ozono S, Richmond GW, Sakovich I, Salzer U, Schuetz C, Seeborg FO, Sharapova SO, Sockel K, Volokha A, von Bonin M, Warnatz K, Wegehaupt O, Weinberg GA, Wong KJ, Worth A, Yu H, Zharankova Y, Zhao X, Devlin L, Badarau A, Csomos K, Keszei M, Pereira J, Taveras AG, Beaussant-Cohen SL, Ong MS, Shcherbina A, Walter JE

Dose-dependent association between inhaled corticosteroid use and risk of obesity and metabolic syndrome in asthma.
Wangberg H, Mortazavi D, Kitsen J, Sanni A, Leibel S, Geng B

Mepolizumab prefilled syringe for the treatment of severe eosinophilic asthma: focus on the pediatric population.
Revier MD, Geng B

Atopic dermatitisReview of comorbidities and therapeutics.
Appiah MM, Haft MA, Kleinman E, Laborada J, Lee S, Loop L, Geng B, Eichenfield LF

Balancing B cell responses to the allograft: implications for vaccination.
Crane C, Loop L, Anterasian C, Geng B, Ingulli E

A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.
Dellon ES, Khoury P, Muir AB, Liacouras CA, Safroneeva E, Atkins D, Collins MH, Gonsalves N, Falk GW, Spergel JM, Hirano I, Chehade M, Schoepfer AM, Menard-Katcher C, Katzka DA, Bonis PA, Bredenoord AJ, Geng B, Jensen ET, Pesek RD, Feuerstadt P, Gupta SK, Lucendo AJ, Genta RM, Hiremath G, McGowan EC, Moawad FJ, Peterson KA, Rothenberg ME, Straumann A, Furuta GT, Aceves SS

A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.
Dellon ES, Khoury P, Muir AB, Liacouras CA, Safroneeva E, Atkins D, Collins MH, Gonsalves N, Falk GW, Spergel JM, Hirano I, Chehade M, Schoepfer AM, Menard-Katcher C, Katzka DA, Bonis PA, Bredenoord AJ, Geng B, Jensen ET, Pesek RD, Feuerstadt P, Gupta SK, Lucendo AJ, Genta RM, Hiremath G, McGowan EC, Moawad FJ, Peterson KA, Rothenberg ME, Straumann A, Furuta GT, Aceves SS

Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole.
Dilley M, Geng B

Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma.
Geng B, Dixon AE, Ko J, Janampally P, Haselkorn T, Holweg CTJ, Casale TB, Jarjour N

The impact of maternal asthma on the preterm infants' gut metabolome and microbiome (MAP study).
Bai-Tong SS, Thoemmes MS, Weldon KC, Motazavi D, Kitsen J, Hansen S, Furst A, Geng B, Song SJ, Gilbert JA, Bode L, Dorrestein PC, Knight R, Leibel SA, Leibel SL

Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
Geng B, Bachert C, Busse WW, Gevaert P, Lee SE, Niederman MS, Chen Z, Lu X, Khokhar FA, Kapoor U, Pandit-Abid N, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B

Small molecule drugs for atopic dermatitis, rheumatoid arthritis, and hereditary angioedema.
Geng B, Craig TJ

Activated phosphoinositide 3-kinase δ syndrome associated with nephromegaly, growth hormone deficiency, bronchiectasis: a case report.
Craig M, Geng B, Wigby K, Phillips SA, Bakhoum C, Naheedy J, Cernelc-Kohan M

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.
Geng B, Hebert AA, Takiya L, Miller L, Werth JL, Zang C, Sanders P, Lebwohl MG

See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.

PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.

Rady Children's updates the Doctor Finder annually. We are not responsible for omissions or errors. Prior to making an appointment, please be sure to check with your health plan to confirm coverage. If you see an error or omission on a physician's profile page, please contact us at refsvc@rchsd.org.